ALNY
Alnylam Pharmaceuticals Inc
256.00$
+2.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
Alnylam Pharmaceuticals Inc (ALNY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 3,714 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 0.2 | 4.3 | 5.7 | 27 | 51 | 96 | 101 | 100 | 83 | 67 | 47 | 51 | 41 | 47 | 90 | 75 | 220 | 493 | 844 | 1,037 | 1,828 | 2,248 | 3,714 | |
| – | 20 | 34 | 46 | 63 | 136 | 118 | 143 | 137 | 132 | 123 | 134 | 230 | 330 | 462 | 578 | 1.8 | 25 | 78 | 140 | 169 | 310 | 323 | 677 | |
| – | 0.2 | 4.3 | 5.7 | 27 | 51 | 96 | 101 | 100 | 83 | 67 | 47 | 51 | 41 | 47 | 90 | 73 | 195 | 415 | 704 | 869 | 1,518 | 1,925 | 3,037 | |
| 3.3 | 13 | 25 | 35 | 50 | 121 | 97 | 109 | 106 | 99 | 87 | 113 | 190 | 276 | 382 | 391 | 505 | 655 | 655 | 792 | 883 | 1,004 | 1,126 | 1,324 | |
| – | 7.5 | 12 | 14 | 17 | 23 | 27 | 40 | 38 | 38 | 45 | 27 | 45 | 61 | 89 | 199 | 382 | 479 | 588 | 621 | 771 | 796 | 976 | 1,211 | |
| 4.2 | 21 | 37 | 49 | 66 | 144 | 124 | 149 | 144 | 138 | 131 | 140 | 235 | 337 | 472 | 590 | 888 | 1,134 | 1,243 | 1,413 | 1,654 | 1,800 | 2,102 | 2,535 | |
| -4.2 | -25 | -32 | -43 | -40 | -93 | -28 | -48 | -44 | -55 | -129 | -93 | -405 | -296 | -425 | -500 | -815 | -939 | -828 | -709 | -785 | -282 | -177 | 502 | |
| 0.0 | 0.0 | 0.7 | 1.0 | 1.0 | 1.1 | 0.9 | 5.4 | 2.3 | 1.2 | 1.0 | 1.1 | 2.6 | 5.9 | 8.3 | 12 | 29 | 109 | 84 | 143 | 156 | 121 | 142 | 253 | |
| – | -30 | -35 | -43 | -35 | -80 | -26 | -47 | -43 | -58 | -117 | -92 | -401 | -290 | -410 | -491 | -761 | -885 | -856 | -852 | -1,127 | -434 | -377 | 323 | |
| -0.1 | -4.6 | 0.4 | -0.6 | -4.9 | 5.2 | 0.7 | 0.6 | 0.5 | -5.8 | -11 | -2.7 | -40 | -25 | -23 | -26 | 0.8 | 0.9 | 2.7 | 0.7 | 4.2 | 6.7 | -99 | 9.4 | |
| -4.1 | -25 | -33 | -43 | -35 | -85 | -26 | -48 | -44 | -58 | -106 | -89 | -360 | -290 | -410 | -491 | -761 | -886 | -858 | -853 | -1,131 | -440 | -278 | 314 | |
| -4.2 | -20 | -30 | -39 | -36 | -75 | -19 | -41 | -38 | -50 | -52 | -83 | -172 | -277 | -409 | -487 | -754 | -885 | -736 | -662 | -927 | -258 | -179 | 631 |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.